By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ArQule, Inc. 

19 Presidential Way

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-994-0300 Fax: 781-376-6019


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Discovery

Collaborations

Roche 

Pfizer 

Daiichi Sankyo, Inc. 





Company News
ArQule, Inc. (ARQL) And National Human Genome Research Institute Of NIH Announce Enrollment Of First Patient In The Phase 1 Proteus Syndrome Trial With ARQ 092 11/17/2015 11:26:03 AM
ArQule, Inc. (ARQL) Presents Data On Tivantinib And Propietary Pipeline At AACR-NCI-EORTC Conference 11/9/2015 11:41:07 AM
ArQule, Inc. (ARQL) To Present Data On Tivantinib, ARQ 087, ARQ 092, And ARQ 751 At AACR-NCI-EORTC Conference 10/27/2015 12:47:02 PM
ArQule, Inc. (ARQL) Announces Publication Of Manuscript Highlighting Activity Of AKT Inhibitor ARQ 092 And Next Generation AKT Inhibitor ARQ 751 In Oncology 10/15/2015 2:21:37 PM
ArQule, Inc. (ARQL) Presents Results From Phase 1b Expansion Study Of ARQ 092 At The 2015 European Cancer Conference 9/28/2015 4:00:24 PM
ArQule, Inc. (ARQL) To Present At Leerink Partners 4th Annual Rare Disease Roundtable On September 30, 2015 9/25/2015 9:03:30 AM
ArQule, Inc. (ARQL) To Report Second Quarter 2015 Financial Results On August 5, 2015 7/29/2015 10:52:41 AM
ArQule, Inc. (ARQL) Announces Interim Phase II Study Results For Tivantinib In Combination With Cetuximab In Patients With MET-High, KRAS Wild Type Colorectal Cancer Presented At ESMO World Congress On Gastrointestinal Cancer 2015 7/6/2015 7:42:31 AM
ArQule, Inc. (ARQL) Appoints Robert J. Weiskopf As Chief Financial Officer 6/1/2015 1:46:37 PM
ASCO15: ArQule, Inc. (ARQL) Announces Data Presentations With Tivantinib And ARQ 087 To Be Featured At ASCO 2015 6/1/2015 1:35:45 PM
12345678910...
//-->